Vol. 19/No. 1 | OncologyLive

Novel Approaches Show Promise in Targeting JAK Pathway

February 12, 2018

Dysregulation of the JAK pathway plays a role in the development of numerous tumor types; it is particularly central to the pathophysiology of myelofibrosis and has long been recognized as a potentially valuable therapeutic target in that malignancy.

Missing in Action: Patient Perspective on Cancer Trial Goal

January 14, 2018

There is a critically important subject associated with the clinical trial experience that has had inadequate discussion within the medical literature, regarding the role of the patient beyond agreeing to serve as a research subject.

FGFR Inhibitor Tested in Hard-to-Treat GI Cancer

January 13, 2018

Given that few options are available for intrahepatic cholangiocarcinoma, investigators are excited about a phase III trial of the multikinase inhibitor derazantinib as a second-line treatment for patients with inoperable or advanced disease.